Abbott and Roche hosted their respective Q3 ’19 earnings calls and provided updates to their diabetes businesses. Of note, Abbott confirmed that Libre 2 US approval is delayed from initial expectations, and Abbott indicated they are working through several items with FDA. Below, FENIX provides highlights and insights from the respective calls.